Data from: Immune checkpoint inhibitor–related myositis and myocarditis in patients with cancer
Mehdi Touat, Thierry Maisonobe, Samuel Knauss, Omar Ben Hadj Salem, Baptiste Hervier, Karine Auré, Tali-Anne Szwebel, Nora Kramkimel, Claire Lethrosne, Jean-Frédéric Bruch, Pauline Laly, Jacques Cadranel, Nicolas Weiss, Anthony Béhin, Yves Allenbach, Olivier Benveniste, Timothée Lenglet, Dimitri Psimaras, Werner Stenzel & Sarah Léonard-Louis
Objective: To report the clinicopathological features and outcome of myositis in patients treated with immune checkpoint inhibitors (irMyositis). Methods: We retrospectively analyzed patients diagnosed with irMyositis in tertiary centers in Paris, France, and Berlin, Germany, from January 2015, to July 2017. Main outcomes were clinical manifestations and muscle histology, which included MHC-I, C5b-9, CD3, CD4, CD8, CD20, CD68, PD-1, PD-L1 and PD-L2 immunohistochemical stains. Results: Ten patients with metastatic cancer were included; median age was...